Format

Send to

Choose Destination
Heart. 2018 Oct;104(19):1568-1574. doi: 10.1136/heartjnl-2017-312106. Epub 2018 May 2.

Pulmonary arterial hypertension in adult congenital heart disease.

Brida M1,2,3,4, Gatzoulis MA1,2.

Author information

1
Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK.
2
National Heart and Lung Institute, Imperial College, London, UK.
3
Division of Adult Congenital and Valvular Heart Disease, Department of Cardiovascular Medicine, University Hospital Muenster, Muenster, Germany.
4
Division for Adult Congenital Heart Disease, Department of Cardiovascular Medicine, University Hospital Centre Zagreb, Zagreb, Croatia.

Abstract

Pulmonary arterial hypertension (PAH) is commonly associated with congenital heart disease (CHD) and relates to type of the underlying cardiac defects and repair history. Large systemic to pulmonary shunts may develop PAH if untreated or repaired late. PAH, when present, markedly increases morbidity and mortality in patients with CHD. Significant progress has been made for patients with Eisenmenger syndrome in pathophysiology, prognostication and disease-targeting therapy (DTT), which needs to be applied to routine patient care. Patients with PAH-CHD and systemic to pulmonary shunting may benefit from late defect closure if pulmonary vascular resistance (PVR) is still normal or near normal. Patients with PAH and coincidental defects, or previous repair of CHD should be managed as those with idiopathic PAH. Patients with a Fontan circulation, despite not strictly fulfilling criteria for PAH, may have elevated PVR; recent evidence suggests that they may also benefit from DTT, but more data are required before general recommendations can be made. CHD-PAH is a lifelong, progressive disease; patients should receive tertiary care and benefit from a proactive DTT approach. Novel biomarkers and genetic advances may identify patients with CHD who should be referred for late defect closure and/or patients at high risk of developing PAH despite early closure in childhood. Ongoing vigilance for PAH and further controlled studies are clearly warranted in CHD.

KEYWORDS:

congenital heart disease; pulmonary vascular disease; secondary pulmonary hypertension

Conflict of interest statement

Competing interests: MAG is a steering committee member for Actelion Pharmaceuticals and has received unrestricted educational grants from Actelion Pharmaceuticals, Pfizer and GlaxoSmithKline.

Publication type

Publication type

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center